miR-221/222 are involved in response to sunitinib treatment in metastatic renal cell carcinoma

Molecular Therapy

Volumn 23, Issue 11, 2015, Pages 1748-1758

  Khella, Heba W Z ^a,b   Butz, Henriett ^a,b   Ding, Qiang ^a   Rotondo, Fabio ^a   Evans, Kenneth R ^c   Kupchak, Peter ^c   Dharsee, Moyez ^c   Latif, Ashraf ^a   Pasic, Maria D ^b   Lianidou, Evi ^d   Bjarnason, Georg A ^e   Yousef, George M ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MaRS Centre   (Canada)

^d UNIVERSITY OF ATHENS   (Greece)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 221; MICRORNA 222; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; MIRN221 MICRORNA, HUMAN; MIRN222 MICRORNA, HUMAN; MTOR PROTEIN, HUMAN; PHARMACOLOGICAL BIOMARKER; PYRROLE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL COMMUNICATION; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; DRUG EFFECTS; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROGNOSIS; SECONDARY; STATISTICAL MODEL; TREATMENT OUTCOME; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDOLES; KIDNEY NEOPLASMS; MICRORNAS; MIDDLE AGED; MODELS, STATISTICAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PYRROLES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84948710661     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.129     Document Type: Article

References (55)

1. Siegel R, Ma J, Zou Z, and Jemal A (2014). Cancer statistics, 2014. CA Cancer J Clin 64: 9-29.
2. Motzer RJ, Hutson TE, McCann L, Deen K, and Choueiri TK (2014). Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 370: 1769-1770.
3. Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, et al. (2013). Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 31: 3791-3799.
4. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. (2009). Overall survival, and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590.
5. Takahashi S (2011). Vascular endothelial growth factor (VEGF), VEGF receptors, and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull 34: 1785-1788.
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
7. Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, et al. (2012). Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol 23: 1549-1555.
8. Bergers G, and Hanahan D (2008). Modes of resistance to anti-Angiogenic therapy. Nat Rev Cancer 8: 592-603.
9. Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, et al. (2010). Reversible epithelial to mesenchymal transition, and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 9: 1525-1535.
10. Osawa T, Tsuchida R, Muramatsu M, Shimamura T, Wang F, Suehiro J, et al. (2013). Inhibition of histone demethylase JMJD1A improves anti-Angiogenic therapy, and reduces tumor-Associated macrophages. Cancer Res 73: 3019-3028.
11. Khella HW, Bakhet M, Lichner Z, Romaschin AD, Jewett MA, and Yousef GM (2013). MicroRNAs in kidney disease: an emerging understanding. Am J Kidney Dis 61: 798-808.
12. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, et al. (2007). Micro-RNA profiling in kidney, and bladder cancers. Urol Oncol 25: 387-392.
13. Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T, et al. (2009). MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 13(9B): 3918-3928.
14. White NM, Bao TT, Grigull J, Youssef YM, Girgis A, Diamandis M, et al. (2011). miRNA profiling for clear cell renal cell carcinoma: biomarker discovery, and identification of potential controls, and consequences of miRNA dysregulation. J Urol 186: 1077-1083.
15. Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, et al. (2014). miR-141 is a key regulator of renal cell carcinoma proliferation, and metastasis by controlling EphA2 expression. Clin Cancer Res 20: 2617-2630.
16. Chow TF, Mankaruos M, Scorilas A, Youssef Y, Girgis A, Mossad S, et al. (2010). The miR-17-92 cluster is over expressed in, and has an oncogenic effect on renal cell carcinoma. J Urol 183: 743-751.
17. Khella HW, Bakhet M, Allo G, Jewett MA, Girgis AH, Latif A, et al. (2013). miR-192, miR-194, and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis 34: 2231-2239.
18. Lichner Z, Mejia-Guerrero S, Ignacak M, Krizova A, Bao TT, Girgis AH, et al. (2012). Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways. Am J Pathol 180: 1675-1687.
19. Heinzelmann J, Unrein A, Wickmann U, Baumgart S, Stapf M, Szendroi A, et al. (2014). MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors, and distant metastases. Ann Surg Oncol 21: 1046-1054.
20. White NM, Khella HW, Grigull J, Adzovic S, Youssef YM, Honey RJ, et al. (2011). miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer 105: 1741-1749.
21. Fridman E, Dotan Z, Barshack I, David MB, Dov A, Tabak S, et al. (2010). Accurate molecular classification of renal tumors using microRNA expression. J Mol Diagn 12: 687-696.
22. Youssef YM, White NM, Grigull J, Krizova A, Samy C, Mejia-Guerrero S, et al. (2011). Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol 59: 721-730.
23. Mascaux C, Feser WJ, Lewis MT, Baron AE, Coldren CD, Merrick DT, et al. (2013). Endobronchial miRNAs as biomarkers in lung cancer chemoprevention. Cancer Prev Res (Phila) 6: 100-108.
24. Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, et al. (2011). Identification of plasma microRNA-21 as a biomarker for early detection, and chemosensitivity of non-small cell lung cancer. Chin J Cancer 30: 407-414.
25. Takahashi M, Cuatrecasas M, Balaguer F, Hur K, Toiyama Y, Castells A, et al. (2012). The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One 7: e46684.
26. He YJ Wu JZ Ji MH, Ma T, Qiao EQ, Ma R, et al. (2013). miR-342 is associated with estrogen receptor-?expression, and response to tamoxifen in breast cancer. Exp Ther Med 5: 813-818.
27. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, et al. (2010). Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70: 1053-1062.
28. Korn C, Scholz B, Hu J, Srivastava K, Wojtarowicz J, Arnsperger T, et al. (2014). Endothelial cell-derived non-canonical Wnt ligands control vascular pruning in angiogenesis. Development 141: 1757-1766.
29. Stefater, JA 3rd, Lewkowich I, Rao S, Mariggi G, Carpenter AC, Burr AR, et al. (2011). Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature 474: 511-515.
30. Suárez Y, Fernández-Hernando C, Pober JS, and Sessa WC (2007). Dicer dependent microRNAs regulate gene expression, and functions in human endothelial cells. Circ Res 100: 1164-1173.
31. Lee-Ying R, Lester R, and Heng D (2014). Current management, and future perspectives of metastatic renal cell carcinoma. Int J Urol 21: 847-855.
32. Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, et al. (2007). Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-Dargeted therapy. Cancer 110: 543-550.
33. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. (2009). Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-Dargeted agents: results from a large, multicenter study. J Clin Oncol 27: 5794-5799.
34. Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, et al. (2008). Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 113: 1552-1558.
35. Park JY, Lee JL, Baek S Eo SH, Go H Ro JY, et al. (2014). Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-Dargeted therapy. Hum Pathol 45: 1437-1444.
36. Prior C, Perez-Gracia JL, Garcia-Donas J, Rodriguez-Antona C, Guruceaga E, Esteban E, et al. (2014). Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One 9: e86263.
37. Berkers J, Govaere O, Wolter P, Beuselinck B, Schöffski P, van Kempen LC, et al. (2013). A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-Domesenchymal transition, and hypoxia resistance. J Urol 189: 1930-1938.
38. Gámez-Pozo A, Anton-Aparicio LM, Bayona C, Borrega P, Gallegos Sancho MI, García-Domínguez R, et al. (2012). MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia 14: 1144-1152.
39. Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, et al. (2008). MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 12(6A): 2189-2204.
40. Teixeira AL, Ferreira M, Silva J, Gomes M, Dias F, Santos JI, et al. (2014). Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tumour Biol 35: 4057-4066.
41. Rong M, Chen G, and Dang Y (2013). Increased miR-221 expression in hepatocellular carcinoma tissues, and its role in enhancing cell growth, and inhibiting apoptosis in vitro. BMC Cancer 13: 21.
42. Lupini L, Bassi C, Ferracin M, Bartonicek, N, D'Abundo L, Zagatti B, et al. (2013). miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs. Front Genet 4: 64.
43. Su A, He S, Tian B, Hu W, and Zhang Z (2013). MicroRNA-221 mediates the effects of PDGF-BB on migration, proliferation, and the epithelial-mesenchymal transition in pancreatic cancer cells. PLoS One 8: e71309.
44. Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, et al. (2010). MicroRNA-221, and microRNA-222 regulate gastric carcinoma cell proliferation, and radioresistance by targeting PTEN. BMC Cancer 10: 367.
45. Hwang MS, Yu N, Stinson SY, Yue P, Newman RJ, Allan BB, et al. (2013). miR-221/222 targets adiponectin receptor 1 to promote the epithelial-Do-mesenchymal transition in breast cancer. PLoS One 8: e66502.
46. Falkenberg N, Anastasov N, Rappl K, Braselmann H, Auer G, Walch A, et al. (2013). MiR-221/-222 differentiate prognostic groups in advanced breast cancers, and influence cell invasion. Br J Cancer 109: 2714-2723.
47. Kuehbacher A, Urbich C, and Dimmeler S (2008). Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci 29: 12-15.
48. Buczek M, Escudier B, Bartnik E, Szczylik C, and Czarnecka A (2014). Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. Biochim Biophys Acta 1845: 31-41.
49. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, et al. (2006). MicroRNAs modulate the angiogenic properties of HUVECs. Blood 108: 3068-3071.
50. Staszel T, Zapala B, Polus A, Sadakierska-Chudy A, Kiec-Wilk B, Stepien E, et al. (2011). Role of microRNAs in endothelial cell pathophysiology. Pol Arch Med Wewn 121: 361-366.
51. Urbich C, Kuehbacher A, and Dimmeler S (2008). Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 79: 581-588.
52. Dornbusch J, Zacharis A, Meinhardt M, Erdmann K, Wolff I, Froehner M, et al. (2013). Analyses of potential predictive markers, and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS One 8: e76386.
53. Terakawa T, Miyake H, Kusuda Y, and Fujisawa M (2013). Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Urol Oncol 31: 493-498.
54. Kim JK, Choi KJ, Lee M Jo MH, and Kim S (2012). Molecular imaging of a cancer-Dargeting theragnostics probe using a nucleolin aptamer-, and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials 33: 207-217.
55. White NM, Bui A, Mejia-Guerrero S, Chao J, Soosaipillai A, Youssef Y, et al. (2010). Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. Biol Chem 391: 411-423.